ramipril / Generic mfg. - LARVOL DELTA

WF-1801: Single-arm pilot study of ramipril for prevention of radiation-induced cognitive decline in glioblastoma patients receiving chemoradiotherapy. (PubMed, Neurooncol Pract) - "The ramipril intervention did not meet the prespecified feasibility endpoint, neither did the cognitive scores differ significantly from the NRG/RTOG 0925 control group. We expect other agents will be the focus of future cytoprotective trials."

Journal • Brain Cancer • Glioblastoma • Oncology • Solid Tumor

Cardioprotection in patients with anthracycline-treated breast cancer: final analysis from the 2 × 2 randomized, placebo-controlled, double-blind SAFE trial. (PubMed, ESMO Open) - "Ramipril and bisoprolol significantly reduce the incidence of subclinical cardiac damage in patients with breast cancer undergoing anthracycline-based chemotherapy, thus supporting their use as early prevention cardioprotective strategies."

Journal • Breast Cancer • Cardiovascular • Oncology • Solid Tumor

Ramipril and Olmesartan: Unveiling their pleiotropic potential as immunomodulators. (PubMed, Indian J Pharmacol) - "The results indicate the immunomodulatory potential of ramipril and olmesartan at equipotent antihypertensive doses, compared with the standard drugs, in Wistar albino rats. The results reveal that olmesartan exhibits superior immunomodulatory properties compared with Ramipril."

Journal • Cardiovascular • Hypertension • Inflammation • CRP

Clinical analyses of angiotensin-converting enzyme inhibitor users presenting with cough to a chest diseases outpatient clinic: A single-center retrospective study. (PubMed, J Int Med Res) - "Perindopril use was more common in the non-pulmonary group, whereas ramipril use was more common among patients with pulmonary cough (p = 0.015). C-reactive protein levels were higher in the pulmonary group (10.87 vs. 5.67 mg/L, p = 0.010), whereas other hematological parameters did not differ significantly.ConclusionsIn the angiotensin-converting enzyme inhibitor-treated patients presenting with cough, shorter symptom duration, absence of dyspnea, and lower C-reactive protein levels may be more compatible with non-pulmonary or presumed angiotensin-converting enzyme inhibitor-related cough, whereas prolonged cough, dyspnea, and elevated C-reactive protein levels may support the consideration of a pulmonary pathology. These findings are hypothesis-generating and require prospective validation."

Journal • Retrospective data • Cardiovascular • Cough • Hematological Disorders • Pulmonary Disease • Respiratory Diseases • CRP

Metabolic and Inflammatory Adverse Drug Reactions Associated with Amlodipine: A Descriptive and Disproportionality Analysis of EudraVigilance Reports. (PubMed, Pharmaceuticals (Basel)) - " "Hyperglycaemia" could be considered a safety signal for amlodipine, compared to beta-blockers (e.g., bisoprolol-ROR: 2.56), ACE inhibitors (e.g., ramipril-ROR: 2.82), and sartans (e.g., candesartan-ROR: 3.85). "Metabolic syndrome" was reported for amlodipine with a lower probability than for hydrochlorothiazide (ROR: 0.35). Inflammatory signals (e.g., increased C-reactive protein) appeared less frequently for amlodipine than for certain renin-angiotensin-aldosterone system inhibitors (e.g., perindopril-ROR: 0.53)...Reports of inflammation likely reflect patient comorbidities rather than a direct drug effect. These findings demonstrate that post-marketing surveillance remains essential, even when accounting for the methodological limitations of spontaneous reporting."

Adverse drug reaction • Journal • Cardiovascular • Diabetes • Genetic Disorders • Hypertension • Inflammation • Metabolic Disorders • Obesity • Type 2 Diabetes Mellitus • CRP

Effect of pentoxifylline on inflammatory markers in non-diabetic chronic kidney disease patients: A prospective, interventional, open label. (PubMed, World J Nephrol) - "In non-diabetic CKD patients, adjunctive treatment with PTX was associated with significant decreases in C-reactive protein levels and proteinuria. The reduction in proteinuria was mainly explained by changes in mean arterial pressure, followed by changes in TNF-α, indicating that hemodynamic factors may play a more prominent role than inflammatory modulation in mediating this effect."

Journal • Chronic Kidney Disease • Diabetic Nephropathy • Metabolic Disorders • Nephrology • Oncology • Renal Disease • CRP • IL6 • TNFA

Renin-Angiotensin System Inhibitor Use and Mortality in Older Hypertensive Patients With and Without Dementia: A Nationwide Registry-Based Cohort Study. (PubMed, J Clin Hypertens (Greenwich)) - "Cox regressions compared mortality risk among RASI users versus non-users, ACEI users versus ARB users, and users of enalapril, ramipril, losartan, and candesartan versus other RASI users. RASI use was associated with lower all-cause mortality among older hypertensive patients, including those with dementia. These observational findings support continued attention to evidence-based hypertension treatment in patients with dementia."

Journal • Alzheimer's Disease • Cardiovascular • CNS Disorders • Dementia • Hypertension

Digital pharmacoepidemiology of angiotensin-converting enzyme inhibitors in Russia. (PubMed, Front Pharmacol) - "Search queries were analyzed for six major ACE inhibitors (captopril, enalapril, lisinopril, perindopril, ramipril, fosinopril), as well as for their brand names (21 drugs in total). The identified digital patterns may indirectly reflect medication-related information needs and potential gaps in the population's health literacy. The infodemiological approach represents a promising tool for monitoring patients' information needs and optimizing clinical communication and preventive programs."

Journal • Cardiovascular • Hypertension

CRACOVIA-HF: The Effect of Sacubitril/Valsartan Versus Ramipril on Left Ventricular Function and Remodeling in Patients With Ischemic Heart Failure With Mid-range Ejection Fraction (clinicaltrials.gov) - P3 | N=488 | Recruiting | Sponsor: John Paul II Hospital, Krakow | Trial completion date: Jun 2027 ➔ Dec 2028 | Trial primary completion date: Mar 2027 ➔ Aug 2028

Trial completion date • Trial primary completion date • Cardiovascular • Congestive Heart Failure • Heart Failure

Discovering the Differences of the Individual Batches of API and its Polymorphs Using Hansen Solubility Parameters. (PubMed, Pharm Res) - "IGC-derived HSP analysis provides complementary, surface-sensitive information that can support excipient selection during early formulation development and help manage risks related to polymorphic variability and supplier-to-supplier differences. Further work should link HSP profiles to formulation performance metrics such as processability, compatibility and stability."

Journal

Real-World Effectiveness and Safety of Ramipril/Indapamide Combination Therapy in Essential Hypertension: A Retrospective Study on UK Primary Care Records. (PubMed, Int J Hypertens) - "Switching from ramipril or indapamide monotherapy to their free combination was associated with clinically meaningful BP decreases, high adherence and persistence, and a favorable safety profile in routine practice. These findings are consistent with current therapeutic guidelines that endorse its use in essential hypertension management."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Cough • Gout • Hypertension • Inflammatory Arthritis • Respiratory Diseases • Rheumatology

Decoding cytokine interactions for psoriasis therapy through computational repurposing of antihypertensive drugs. (PubMed, Sci Rep) - "Lisinopril, Ramipril, Amlodipine, and Atenolol emerged as top candidates based on docking scores and pharmacokinetic profiles. Among them, Lisinopril exhibited the strongest binding affinity across all four cytokines, comparable to or exceeding that of Apremilast...However, these results are purely predictions and should be viewed with caution, especially considering reports of potential ACE inhibitor-related psoriasis worsening. Further thorough laboratory, animal, and clinical studies are necessary to assess its practical application and safety in treating psoriasis."

Journal • Dermatology • Immunology • Inflammation • Psoriasis • IFNG • IL17A • IL1B • IL6

Repurposed Drugs and Cardiovascular Morbidity: A Cost-Effectiveness Analysis. (PubMed, Am J Ther) - "Pharmacoeconomic stratification of repurposed cardiovascular agents identifies 3 distinct tiers. Generic agents-ramipril, carvedilol, metformin, and statins-demonstrate the most favorable cost-effectiveness profiles and should form the basis of any prevention protocol. SGLT2 inhibitors and GLP-1 receptor agonists offer clinically meaningful benefits in secondary prevention when applied to populations meeting pivotal trial eligibility criteria. PCSK9 inhibitors remain cost-effective only in patients with very high cardiovascular risk and inadequate LDL control on maximally tolerated statin therapy."

HEOR • Journal • Cardiovascular • Congestive Heart Failure • Heart Failure

The Efficacy of Antihypertensive Drugs and miR-632 Inhibition on Parietal Remodeling in a Model of Marfan Thoracic Aortic Aneurysm. (PubMed, Biomolecules) - "Our data emphasize that choosing the right treatment in MFS aortopathy requires understanding its specific impact on cellular pathways. Our findings identify losartan as the most effective standard drug in this model, while suggesting miR-632 as a potential future target to stabilize the aortic wall and, prospectively, delay surgery."

Journal • Cardiovascular • Genetic Disorders • Rheumatology • TGFB1

A dual-matrix analytical framework integrating bio-inspired machine learning and Sobol-optimized UV spectrophotometry for five-analyte quantification: comprehensive sustainability assessment. (PubMed, BMC Chem) - "In the present study, a dual-matrix chemometric framework was developed for the simultaneous determination of five spectrally overlapping analytes-hydrochlorothiazide (HCD), losartan potassium (LOS), ramipril (RAP), N-nitrosodiethylamine (NDA), and toluene (TLN)-in pharmaceutical formulations and fortified human plasma samples. To the best of our knowledge, no previous UV spectrophotometric chemometric method has been reported for the simultaneous determination of LOS, RAP, and HCD in the presence of both NDA and TLN within a single analytical workflow without a prior separation step. The proposed dual-matrix FA-PLS framework demonstrates that UV spectrophotometry, when coupled with advanced chemometric optimization and statistically designed calibration strategies, can provide an accurate, sensitive, and environmentally sustainable platform for multicomponent pharmaceutical analysis and proof-of-concept application to biological matrices."

Journal

De Novo Hypertensive Scleroderma Renal Crisis in a Renal Allograft Recipient (ERA 2026) - "She was immunosuppressed with mycophenolate mofetil (MMF) and tacrolimus; other medications included antihypertensives and long- term moderate dose prednisolone...Accordingly, IV methylprednisolone was started as an inpatient...Management included iloprost and an increased dose of MMF. Prednisolone was stopped and ramipril commenced...The case demonstrates that the vasculopathy underlying SRC can affect the microvasculature of a renal allograft, even where the native kidney was unaffected. The risk associated with anti-RNA Polymerase III autoantibodies extends to transplanted kidneys, suggesting potential applicability in surveillance and risk stratification of SRC in renal transplant recipients with SSc."

Antibody-mediated Rejection • Cardiovascular • Chronic Kidney Disease • Diabetic Nephropathy • Hypertension • Immunology • Inflammation • Interstitial Lung Disease • Nephrology • Pneumonia • Scleroderma • Systemic Sclerosis

Hypertension and myocardial fibrosis: A systematic review and meta-analysis. (PubMed, Clin Radiol) - "The extent of MF is closely associated with various factors, underscoring the importance of its identification in hypertensive patients. Histology and T1 mapping parameters are effective for quantifying MF. Due to the variable effects of antihypertensive medications on MF, the use of specific agents to mitigate MF in hypertensive patients is recommended."

Journal • Retrospective data • Cardiovascular • Congestive Heart Failure • Fibrosis • Heart Failure • Hypertension • Immunology

Antiproteinuric effect of angiotensin-converting enzyme inhibitors in children with X-linked Alport syndrome in detail (ERA 2026) - "Method The single-center cohort study included XLAS children (n=76; 51 males; foloow up ≥ 5 yrs) with proteinuria (Pr) treated with ACEi (age 8,6±2,5 yrs, 7,5±2,3 and 8,3±3,7 yrs in boys and girls, respectively, p=0,822; initial ACEi dosage by ramipril 3,6±0,9 mg/m 2 /day, 4,1±0,8 and 2,1±0,5 mg/m 2 /day in boys and girls, respectively, p=0,036)...Pr increased to the initial level by 14,1±1,8 month of the treatment (18,1±1,2, 14,3±1,1, 10,2±1,3 months pts with Pr 0,05). Conclusion The antiproteinuric effect of ACEi in children with XLAS is transient and depends on initial level of proteinuria."

Clinical • Chronic Kidney Disease • Genetic Disorders • Glomerulonephritis • Nephrology • Renal Disease

Real life use of Iptacopan in C3 Glomerulopathy with a particular genetic variant in Romania (ERA 2026) - "The patient was initially treated with Ramipril 5 mg/day and, although the UPCR decreased to 512 mg/g, the hematuria increased to >50 RBC/HPF. She was started on prednisolone 20 mg/day and mycophenolate mofetil (MMF)...It underscores the value of integrating genetic testing, complement studies, and renal histopathology to guide personalized management in C3G. Image"

Clinical • Complement-mediated Rare Disorders • Glomerulonephritis • Hepatology • Infectious Disease • Inflammation

Targeted-Release Budesonide (Kinpeygo®) for IgA Nephropathy During Pregnancy: First Report of Maternal and Foetal Safety (ERA 2026) - "She achieved disease stability on optimised supportive therapy including ramipril and dapagliflozin...Delivery occurred at 37 weeks term due to fetal distress, with hypertension developing after delivery, treated with Nifedipine and Labetalol...While limited by its single-case nature, this report suggests that targeted-release budesonide may be considered in carefully selected pregnant patients within a multidisciplinary setting and supports further clinical study. Image"

Clinical • Cardiovascular • Chronic Kidney Disease • Glomerulonephritis • Gynecology • Hypertension • IgA Nephropathy • Lupus Nephritis • Obstetrics • Renal Disease

Amazonian toxoplasmosis complicated by severe hypoxemic pneumonia and myopericarditis in an immunocompetent adult. (PubMed, BMC Infect Dis) - "This case illustrates that AT may lead to severe complications, including myopericarditis, even in previously healthy individuals, a presentation that is very rarely reported in the literature. The diagnosis is challenging due to nonspecific early symptoms, overlap with other tropical infections, and limited access to advanced imaging in remote areas. Clinicians practicing in endemic regions should consider toxoplasmosis in the differential diagnosis of unexplained pneumonia, pericarditis or myocarditis."

Journal • Cardiovascular • Dengue Fever • Heart Failure • Infectious Disease • Inflammation • Musculoskeletal Pain • Pain • Pneumonia • Respiratory Diseases • Septic Shock

AIFA-CARDIO-129: Pharmacological optimization in prevention in Heart Failure: A Sex-gap? (clinicaltrialsregister.eu) - P4 | N=368 | Recruiting | Sponsor: Policlinico San Donato S.p.A. | Not yet recruiting ➔ Recruiting

Enrollment open • Cardiovascular • Congestive Heart Failure • Heart Failure

Drug-induced psoriasis following sacubitril/valsartan: a case report and literature review. (PubMed, BMC Cardiovasc Disord) - "To the best of our knowledge, this is the first reported case worldwide of psoriasis potentially associated with SV, and the underlying mechanism appears likely to be related to sacubitril. It serves as a caution for clinicians prescribing SV, particularly in patients with a history of psoriasis or positivity for the HLA-Cw*0602 allele. Further studies are warranted to confirm the mechanism by which sacubitril induces psoriasis."

Journal • Cardiovascular • Congestive Heart Failure • Dermatology • Heart Failure • Hypertension • Hypotension • Immunology • Psoriasis • Renal Disease

Cardiovascular events after acute myocardial infarction complicated by low ejection fraction and/or congestion: a landmark analysis of the PARADISE-MI trial. (PubMed, Eur J Heart Fail) - "Post-AMI, HF predominates both early and late among CV events. Compared with ramipril, sacubitril/valsartan was associated with a possible late reduction in recurrent MI and a modest decrease in an expanded CV composite outcome that merits further investigation."

Journal • Cardiovascular • Congestive Heart Failure • Heart Failure • Myocardial Infarction

Adverse event of ACE inhibitors: A descriptive analysis of FAERS data. (PubMed, J Public Health Res) - "This retrospective pharmacovigilance study analyzed FAERS reports submitted from January 1, 1979, through March 31, 2025, for nine ACE inhibitors (benazepril, captopril, enalapril, fosinopril, lisinopril, moexipril, quinapril, ramipril, and trandolapril) identified as primary suspect drugs. Adults and elderly patients carry the highest burden of ADEs, though pediatric cases remain clinically relevant for specific agents. These findings support tailored monitoring and risk mitigation strategies in clinical practice."

Adverse events • Journal • Acute Kidney Injury • Cardiovascular • Cough • Hypertension • Hypotension • Nephrology • Pediatrics • Renal Disease • Respiratory Diseases